Showing results (291-300 of 378) with videos related to

Sort By:
Pageof 38
Annals of Nuclear Medicine|April 16, 2009
A recovery coefficient method for partial volume correction of PET imagesShyam M Srinivas, Thiruvenkatasamy Dhurairaj, Sandip Basu, et al.
Seminars in Nuclear Medicine|February 4, 2009
Functional imaging of inflammatory diseases using nuclear medicine techniquesSandip Basu, Hongming Zhuang, Drew A Torigian, et al.
Hellenic Journal of Nuclear Medicine|November 26, 2009
Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observationGonca Bural, Drew A Torigian, Mohamed Houseni, et al.
Clinical Nuclear Medicine|July 14, 2020
Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE TreatmentRahul V Parghane, Arpit Mitra, Trupti Upadhye, et al.
Clinical Nuclear Medicine|June 12, 2013
Adverse functional effects of chemotherapy on whole-brain metabolism: a PET/CT quantitative analysis of FDG metabolic pattern of the "chemo-brain"Jordan Sorokin, Babak Saboury, JinHyung Albert Ahn, et al.
Nuclear Medicine Communications|June 1, 2016
Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristicsPradeep Thapa, Rohit Ranade, Vikas Ostwal, et al.
Nuclear Medicine Communications|May 22, 2026
Efficacy of intra-arterial [177Lu]Lu-DOTATATE vs. continuation intravenous [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy in nonresponding locally advanced inoperable or liver-dominant metastatic gastroenteropancreatic neuroendocrine tumorsRangat Bagasariya, Rahul Vithalrao Parghane, Nitin Shetty, et al.
The Prostate|September 1, 2021
Combined 177 Lu-PSMA-617 PRLT and abiraterone acetate versus 177 Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durabilitySonam Suman, Rahul V Parghane, Amit Joshi, et al.
Hellenic Journal of Nuclear Medicine|November 17, 2011
Evaluation of diagnostic performance of 18F-FDG-PET compared to CT in detecting potential causes of fever of unknown origin in an academic centreJoshua Rosenbaum, Sandip Basu, Samuel Beckerman, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 3, 2013
Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: a pilot studySarah Abdulla, Ali Salavati, Babak Saboury, et al.
Pageof 38